STC1 and acute myeloid leukemia: As neutralizing experiments consume large quantities of antibody and primary AML samples take longer to engraft, thus extending the period for which anti-STC1 is needed, we restricted our analysis to 2 AML cell lines: U937 and OCI-AML3.